ASTH vs TGTX: fair value comparison
Astrana Health, Inc. and TG Therapeutics, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, TGTX currently sits closer to the top of our discount ranking.
| ASTH | TGTX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.91 | $46.17 |
| 12-month range | $22.32–$49.81 | $29.18–$53.52 |
| Sector rank | #7 of 113 Healthcare | #2 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | High | — |
| Margin trend | — | Contracting |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ASTH fair value analysis · TGTX fair value analysis